Prospective Grant of Exclusive Patent License: Composition and Methods for Delivering Inhibitory Oligonucleotides for the Treatment of Pancreatic Cancer, 31783-31784 [2017-14370]
Download as PDF
Federal Register / Vol. 82, No. 130 / Monday, July 10, 2017 / Notices
their presentation on or before July 12,
2017. Time allotted for each
presentation may be limited. If the
number of registrants requesting to
speak is greater than can be reasonably
accommodated during the scheduled
open public hearing session, FDA may
conduct a lottery to determine the
speakers for the scheduled open public
hearing session. The contact person will
notify interested persons regarding their
request to speak by July 13, 2017.
Persons attending FDA’s advisory
committee meetings are advised that the
Agency is not responsible for providing
access to electrical outlets.
FDA welcomes the attendance of the
public at its advisory committee
meetings and will make every effort to
accommodate persons with disabilities.
If you require accommodations due to a
disability, please contact Philip Bautista
at least 7 days in advance of the
meeting.
FDA is committed to the orderly
conduct of its advisory committee
meetings. Please visit our Web site at
https://www.fda.gov/
AdvisoryCommittees/
AboutAdvisoryCommittees/
ucm111462.htm for procedures on
public conduct during advisory
committee meetings.
Notice of this meeting is given under
the Federal Advisory Committee Act (5
U.S.C. app. 2).
virus outbreak in the Americas. The
document was published with the
incorrect docket number. This
document corrects that error.
FOR FURTHER INFORMATION CONTACT: Lisa
Granger, Office of Policy and Planning,
Food and Drug Administration, 10903
New Hampshire Ave., Bldg. 32, Rm.
3330, Silver Spring, MD 20993–0002,
301–796–9115.
SUPPLEMENTARY INFORMATION: In the
Federal Register of Friday, June 30,
2017, in FR Doc. 2017–13720, on page
29866, the following correction is made:
1. On page 29866, in the first column,
in the headings section at the beginning
of the document, the docket number is
corrected to read ‘‘FDA–2016–N–1486’’.
Dated: June 29, 2017.
Anna K. Abram,
Deputy Commissioner for Policy, Planning,
Legislation, and Analysis.
AGENCY:
[FR Doc. 2017–14364 Filed 7–7–17; 8:45 am]
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2016–N–1486]
Authorizations of Emergency Use of In
Vitro Diagnostic Devices for Detection
of Zika Virus; Availability; Correction
Food and Drug Administration,
HHS.
ACTION:
Notice; correction.
The Food and Drug
Administration is correcting a notice
entitled ‘‘Authorizations of Emergency
Use of In Vitro Diagnostic Devices for
Detection of Zika Virus; Availability’’
that appeared in the Federal Register of
June 30, 2017 (82 FR 29886). The
document announced the issuance of
two Emergency Use Authorizations for
in vitro diagnostic devices for detection
of the Zika virus in response to the Zika
sradovich on DSK3GMQ082PROD with NOTICES
SUMMARY:
VerDate Sep<11>2014
16:08 Jul 07, 2017
Jkt 241001
[FR Doc. 2017–14365 Filed 7–7–17; 8:45 am]
BILLING CODE 4164–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Prospective Grant of Exclusive Patent
License: Composition and Methods for
Delivering Inhibitory Oligonucleotides
for the Treatment of Pancreatic Cancer
National Institutes of Health,
Department of Health and Human
Services.
ACTION: Notice.
The National Institute on
Aging, an institute of the National
Institutes of Health, Department of
Health and Human Services, is
contemplating the grant of an Exclusive
Patent License to practice the inventions
embodied in the U.S. Patents and Patent
Applications listed in the
Supplementary Information section of
this notice to VeriLuce Therapeutics
(‘‘VLT’’) located in Toronto, ON,
Canada.
DATES: Only written comments and/or
applications for a license which are
received by the National Cancer
Institute’s Technology Transfer Center
on or before July 25, 2017 will be
considered.
ADDRESSES: Requests for copies of the
patent application, inquiries, and
comments relating to the contemplated
Exclusive Patent License should be
directed to: Surekha Vathyam, Ph.D.,
Senior Technology Transfer Manager,
NCI Technology Transfer Center, 9609
Medical Center Drive, RM 1E530 MSC
9702, Bethesda, MD 20892–9702 (for
SUMMARY:
BILLING CODE 4164–01–P
AGENCY:
Dated: June 30, 2017.
Anna K. Abram,
Deputy Commissioner for Policy, Planning,
Legislation, and Analysis.
PO 00000
Frm 00034
Fmt 4703
Sfmt 4703
31783
business mail), Rockville, MD 20850–
9702 Telephone: (240) 276–5530;
Facsimile: (240) 276–5504 Email:
vathyams@mail.nih.gov.
SUPPLEMENTARY INFORMATION:
Intellectual Property
• United States Provisional Patent
Application No. 61/045,088, filed April
15, 2008, titled ‘‘Composition and
methods for delivering inhibitory
oligonucleotides’’, [HHS Reference No.
E–051–2008/0–US–01], status: expired;
• International Patent Application
No. PCT/US2009/040607, filed April 15,
2009, titled ‘‘Composition and methods
for delivering inhibitory
oligonucleotides’’, [HHS Reference No.
E–051–2008/0–PCT–02], status:
converted;
• Canadian Patent Application No.
2,720,363, filed April 15, 2009, titled
‘‘Composition and methods for
delivering inhibitory oligonucleotides’’,
[HHS Reference No. E–051–2008/0–CA–
04], status: pending;
• United States Patent Application
No. 12/988,148, filed March 8, 2011,
titled ‘‘Compositions and methods for
delivering inhibitory oligonucleotides’’
[HHS Reference No. E–051–2008/0–US–
07], status: issued as Patent No.
8,703,921;
• United States Patent Application
No. 14/220,726, filed March 20, 2014,
titled ‘‘Compositions and Methods for
delivering inhibitory oligonucleotides’’
[HHS Reference No. E–051–2008/0–US–
08], status: issued as Patent No.
9,415,116; and
• United States Patent Application
No. 15,204,789, filed July 7, 2016, titled
‘‘Compositions and Methods for
delivering inhibitory oligonucleotides’’
[HHS Reference No. E–051–2008/0–US–
11], status: pending.
The patent rights in these inventions
have been assigned to the government of
the United States of America.
The prospective exclusive license
territory may be worldwide and the
field of use may be limited to the use
of Licensed Patent Rights for the
following: ‘‘Treatment of pancreatic
cancer by targeting regulatory T cells
using complexes or fusion molecules
comprising inhibitory nucleic acids, a
nucleic acid binding moiety and a
targeting polypeptide, wherein the
targeting polypeptide contains either the
TARC/CCL17 or RANTES/CCL5 cell
surface receptor ligand.’’
Despite significant attractiveness of
anti-sense oligonucleotide technology,
its clinical application has been
precluded by a lack of methods for
targeted delivery and transduction of
primary immune cells in vivo. Novel
complexes and methods for delivering
E:\FR\FM\10JYN1.SGM
10JYN1
sradovich on DSK3GMQ082PROD with NOTICES
31784
Federal Register / Vol. 82, No. 130 / Monday, July 10, 2017 / Notices
inhibitory nucleic acids to cells in a
targeted and efficient manner are
disclosed in this invention. The
complexes and methods are based on
utilizing a cell surface receptor targeting
ligand and a nucleic acid binding
domain that binds an inhibitory nucleic
acid, to efficiently deliver the inhibitory
oligonucleotide to the cell that
expresses the cell surface receptor
targeting ligand. The compositions can
be used to silence gene expression in a
cell or to deliver agents to a target cell,
thereby treating or preventing a disease
or disorder.
The invention has broad utility as the
cell surface receptor targeting ligand
could be any molecule such as,
cytokines, chemokines, antibodies or
growth factors, that binds to a unique
cellular receptor or cell surface antigen.
Cytokines are small secreted proteins
which mediate and regulate immunity,
inflammation, and hematopoiesis.
Chemokines are a family of small
cytokines that are secreted by cells.
They act on their target cells by binding
specific membrane receptors. TARC/
CCL17 and RANTES/CCL5 are examples
of chemokines whose receptors are
CCR4 and CCR5, respectively.
The complexes of this invention
could inactivate immune cells by
delivering oligonucleotides. For
example, the TARC-nucleic acid
binding domain complex referred to as
TARC-arp, has been shown to deliver siFoxP3 oligonucleotide into CCR4expressing cancer cells that will
specifically only inactivate FoxP3
expression. Chemokine-based gene
silencing can be therapeutically used to
modulate immune cells and improve
outcome of diseases, such as by
inactivating Tregs to block cancer
escape and metastasis.
This notice is made in accordance
with 35 U.S.C. 209 and 37 CFR part 404.
The prospective Exclusive Patent
License will be royalty bearing and may
be granted unless within fifteen (15)
days from the date of this published
notice, the National Cancer Institute
receives written evidence and argument
that establishes that the grant of the
license would not be consistent with the
requirements of 35 U.S.C. 209 and 37
CFR part 404.
Complete applications for a license in
the prospective field of use that are filed
in response to this notice will be treated
as objections to the grant of the
contemplated Exclusive Patent License
Agreement. Comments and objections
submitted to this notice will not be
made available for public inspection
and, to the extent permitted by law, will
not be released under the Freedom of
Information Act, 5 U.S.C. 552.
VerDate Sep<11>2014
16:08 Jul 07, 2017
Jkt 241001
Dated: June 27, 2017.
Richard U. Rodriguez,
Associate Director, Technology Transfer
Center, National Cancer Institute.
[FR Doc. 2017–14370 Filed 7–7–17; 8:45 am]
BILLING CODE 4140–01–P
INTERNATIONAL TRADE
COMMISSION
[USITC SE–17–027]
Sunshine Act Meeting
United
States International Trade Commission.
TIME AND DATE: July 12, 2017 at 11:00
a.m.
PLACE: Room 101, 500 E Street SW.,
Washington, DC 20436, Telephone:
(202) 205–2000.
STATUS: Open to the public.
MATTERS TO BE CONSIDERED:
1. Agendas for future meetings: None.
2. Minutes.
3. Ratification List.
4. Vote in Inv. No. 731–TA–410
(Fourth Review) (Light-Walled
Rectangular Pipe from Taiwan). The
Commission is currently scheduled to
complete and file its determination and
views of the Commission by July 25,
2017.
5. Vote in Inv. No. 731–TA–703
(Fourth Review) (Furfuryl Alcohol from
China). The Commission is currently
scheduled to complete and file its
determination and views of the
Commission by July 28, 2017.
6. Outstanding action jackets: None.
In accordance with Commission
policy, subject matter listed above, not
disposed of at the scheduled meeting,
may be carried over to the agenda of the
following meeting.
AGENCY HOLDING THE MEETING:
By order of the Commission.
Issued: July 5, 2017.
William R. Bishop,
Supervisory Hearings and Information
Officer.
[FR Doc. 2017–14450 Filed 7–6–17; 11:15 am]
BILLING CODE 7020–02–P
UNITED STATES INTERNATIONAL
TRADE COMMISSION
[USITC SE–17–028]
Sunshine Act Meeting
United
States International Trade Commission.
TIME AND DATE: July 14, 2017 at 11:00
a.m.
PLACE: Room 101, 500 E Street SW.,
Washington, DC 20436, Telephone:
(202) 205–2000.
AGENCY HOLDING THE MEETING:
PO 00000
Frm 00035
Fmt 4703
Sfmt 4703
STATUS:
Open to the public.
MATTERS TO BE CONSIDERED:
1. Agendas for future meetings: none.
2. Minutes.
3. Ratification List.
4. Vote in Inv. Nos. 701–TA–579–580
and 731–TA–1369–1373
(Preliminary)(Fine Denier Polyester
Staple Fiber from China, India, Korea,
Taiwan, and Vietnam). The Commission
is currently scheduled to complete and
file its determinations on July 17, 2017;
views of the Commission are currently
scheduled to be completed and filed on
July 24, 2017.
5. Vote in Inv. Nos. 701–TA–581 and
731–TA–1374–1376 (Preliminary)
(Citric Acid and Certain Citrate Salts
from Belgium, Colombia, and Thailand).
The Commission is currently scheduled
to complete and file its determinations
on July 17, 2017; views of the
Commission are currently scheduled to
be completed and filed on July 24, 2017.
6. Outstanding action jackets: None.
In accordance with Commission
policy, subject matter listed above, not
disposed of at the scheduled meeting,
may be carried over to the agenda of the
following meeting.
By order of the Commission.
Issued: July 5, 2017.
William R. Bishop,
Supervisory Hearings and Information
Officer.
[FR Doc. 2017–14449 Filed 7–6–17; 11:15 am]
BILLING CODE 7020–02–P
DEPARTMENT OF JUSTICE
[OMB Number 1122–0029]
Agency Information Collection
Activities; Proposed eCollection
eComments Requested; Extension of a
Currently Approved Collection
Office on Violence Against
Women, Department of Justice.
ACTION: 30-day notice.
AGENCY:
The Department of Justice,
Office on Violence Against Women
(OVW) will be submitting the following
information collection request to the
Office of Management and Budget
(OMB) for review and approval in
accordance with the Paperwork
Reduction Act of 1995. The proposed
information collection was previously
published on May 18, 2017, allowing for
a 60 day comment period.
DATES: Comments are encouraged and
will be accepted for 30 days until
August 9, 2017.
FOR FURTHER INFORMATION CONTACT:
Written comments and/or suggestion
SUMMARY:
E:\FR\FM\10JYN1.SGM
10JYN1
Agencies
[Federal Register Volume 82, Number 130 (Monday, July 10, 2017)]
[Notices]
[Pages 31783-31784]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-14370]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Prospective Grant of Exclusive Patent License: Composition and
Methods for Delivering Inhibitory Oligonucleotides for the Treatment of
Pancreatic Cancer
AGENCY: National Institutes of Health, Department of Health and Human
Services.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The National Institute on Aging, an institute of the National
Institutes of Health, Department of Health and Human Services, is
contemplating the grant of an Exclusive Patent License to practice the
inventions embodied in the U.S. Patents and Patent Applications listed
in the Supplementary Information section of this notice to VeriLuce
Therapeutics (``VLT'') located in Toronto, ON, Canada.
DATES: Only written comments and/or applications for a license which
are received by the National Cancer Institute's Technology Transfer
Center on or before July 25, 2017 will be considered.
ADDRESSES: Requests for copies of the patent application, inquiries,
and comments relating to the contemplated Exclusive Patent License
should be directed to: Surekha Vathyam, Ph.D., Senior Technology
Transfer Manager, NCI Technology Transfer Center, 9609 Medical Center
Drive, RM 1E530 MSC 9702, Bethesda, MD 20892-9702 (for business mail),
Rockville, MD 20850-9702 Telephone: (240) 276-5530; Facsimile: (240)
276-5504 Email: vathyams@mail.nih.gov.
SUPPLEMENTARY INFORMATION:
Intellectual Property
United States Provisional Patent Application No. 61/
045,088, filed April 15, 2008, titled ``Composition and methods for
delivering inhibitory oligonucleotides'', [HHS Reference No. E-051-
2008/0-US-01], status: expired;
International Patent Application No. PCT/US2009/040607,
filed April 15, 2009, titled ``Composition and methods for delivering
inhibitory oligonucleotides'', [HHS Reference No. E-051-2008/0-PCT-02],
status: converted;
Canadian Patent Application No. 2,720,363, filed April 15,
2009, titled ``Composition and methods for delivering inhibitory
oligonucleotides'', [HHS Reference No. E-051-2008/0-CA-04], status:
pending;
United States Patent Application No. 12/988,148, filed
March 8, 2011, titled ``Compositions and methods for delivering
inhibitory oligonucleotides'' [HHS Reference No. E-051-2008/0-US-07],
status: issued as Patent No. 8,703,921;
United States Patent Application No. 14/220,726, filed
March 20, 2014, titled ``Compositions and Methods for delivering
inhibitory oligonucleotides'' [HHS Reference No. E-051-2008/0-US-08],
status: issued as Patent No. 9,415,116; and
United States Patent Application No. 15,204,789, filed
July 7, 2016, titled ``Compositions and Methods for delivering
inhibitory oligonucleotides'' [HHS Reference No. E-051-2008/0-US-11],
status: pending.
The patent rights in these inventions have been assigned to the
government of the United States of America.
The prospective exclusive license territory may be worldwide and
the field of use may be limited to the use of Licensed Patent Rights
for the following: ``Treatment of pancreatic cancer by targeting
regulatory T cells using complexes or fusion molecules comprising
inhibitory nucleic acids, a nucleic acid binding moiety and a targeting
polypeptide, wherein the targeting polypeptide contains either the
TARC/CCL17 or RANTES/CCL5 cell surface receptor ligand.''
Despite significant attractiveness of anti-sense oligonucleotide
technology, its clinical application has been precluded by a lack of
methods for targeted delivery and transduction of primary immune cells
in vivo. Novel complexes and methods for delivering
[[Page 31784]]
inhibitory nucleic acids to cells in a targeted and efficient manner
are disclosed in this invention. The complexes and methods are based on
utilizing a cell surface receptor targeting ligand and a nucleic acid
binding domain that binds an inhibitory nucleic acid, to efficiently
deliver the inhibitory oligonucleotide to the cell that expresses the
cell surface receptor targeting ligand. The compositions can be used to
silence gene expression in a cell or to deliver agents to a target
cell, thereby treating or preventing a disease or disorder.
The invention has broad utility as the cell surface receptor
targeting ligand could be any molecule such as, cytokines, chemokines,
antibodies or growth factors, that binds to a unique cellular receptor
or cell surface antigen. Cytokines are small secreted proteins which
mediate and regulate immunity, inflammation, and hematopoiesis.
Chemokines are a family of small cytokines that are secreted by cells.
They act on their target cells by binding specific membrane receptors.
TARC/CCL17 and RANTES/CCL5 are examples of chemokines whose receptors
are CCR4 and CCR5, respectively.
The complexes of this invention could inactivate immune cells by
delivering oligonucleotides. For example, the TARC-nucleic acid binding
domain complex referred to as TARC-arp, has been shown to deliver si-
FoxP3 oligonucleotide into CCR4-expressing cancer cells that will
specifically only inactivate FoxP3 expression. Chemokine-based gene
silencing can be therapeutically used to modulate immune cells and
improve outcome of diseases, such as by inactivating Tregs to block
cancer escape and metastasis.
This notice is made in accordance with 35 U.S.C. 209 and 37 CFR
part 404. The prospective Exclusive Patent License will be royalty
bearing and may be granted unless within fifteen (15) days from the
date of this published notice, the National Cancer Institute receives
written evidence and argument that establishes that the grant of the
license would not be consistent with the requirements of 35 U.S.C. 209
and 37 CFR part 404.
Complete applications for a license in the prospective field of use
that are filed in response to this notice will be treated as objections
to the grant of the contemplated Exclusive Patent License Agreement.
Comments and objections submitted to this notice will not be made
available for public inspection and, to the extent permitted by law,
will not be released under the Freedom of Information Act, 5 U.S.C.
552.
Dated: June 27, 2017.
Richard U. Rodriguez,
Associate Director, Technology Transfer Center, National Cancer
Institute.
[FR Doc. 2017-14370 Filed 7-7-17; 8:45 am]
BILLING CODE 4140-01-P